RxDoctor Payments Data

Seema Ahmed

Family · Chesapeake, VANPI 1386994630

Payments from drug & device makers

$6,505in general payments, 2019–2025

Across 358 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$961
  • Pfizer$664
  • Lilly USA, LLC$502
  • AstraZeneca$425
  • GSK$375
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$6,30297%
  • Education$2033%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,505 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$72,463
Medicare patients
375
Services billed
1,341

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$37,967
EliquisApixaban25$25,893
FarxigaDapagliflozin Propanediol30$25,752
JardianceEmpagliflozin14$18,912
Breo ElliptaFluticasone/Vilanterol19$7,431
BrilintaTicagrelor11$4,968
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$1,117
Atorvastatin Calcium95$734
Albuterol Sulfate HfaAlbuterol Sulfate45$619
Levothyroxine Sodium54$560
Rosuvastatin Calcium45$538
Montelukast Sodium64$510
Pantoprazole Sodium40$432
Amlodipine Besylate76$406
Pravastatin Sodium22$350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$961$37,96742 claims
AstraZenecaFarxiga, Brilinta$425$30,72041 claims
PfizerEliquis$664$25,89325 claims
Boehringer IngelheimJardiance$188$18,91214 claims
GSKBreo Ellipta$375$7,43119 claims
Almatica Pharma LLCSertraline Hcl$51$21133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.

Other family in Chesapeake

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →